Beyond TGFβ1 - novel treatment strategies targeting lung fibrosis

Area of Science:

• Pulmonary Medicine
• Fibrotic Lung Disease Research
• Drug Discovery

Background:

• Fibrosis is a hallmark of chronic lung diseases, stemming from abnormal wound healing processes.
• Transforming growth factor-beta 1 (TGFβ1) is a key driver of fibrosis, targeted by current treatments that offer limited efficacy.
• Airway hyperresponsiveness, inflammation, and infections like COVID-19 are increasingly recognized as contributors to fibrotic lung disease.

Purpose of the Study:

• To review experimental and clinical evidence on novel drugs for fibrotic lung diseases.
• To assess drugs with multifaceted actions against contraction, inflammation, and remodeling.
• To evaluate the potential of these drugs to limit fibrosis progression.

Main Methods:

• Systematic review of experimental and clinical studies.
• Analysis of drug mechanisms targeting airway contraction, inflammation, and remodeling.
• Assessment of drug efficacy in preclinical and clinical models of fibrotic lung disease.

Main Results:

• Novel drug candidates demonstrate complementary actions against key fibrotic pathways.
• Evidence suggests these drugs can oppose airway contraction and inflammation.
• These agents show potential in limiting fibrotic remodeling and disease progression.

Conclusions:

• Emerging therapeutics offer a promising avenue for managing fibrotic lung diseases.
• Repurposing and developing these drugs could lead to more effective treatments.
• Targeting multiple fibrotic mechanisms represents a critical step forward in therapy.